解决 MAFLD：肝脏铁死亡的治疗靶点。
Ironing out MAFLD: Therapeutic targeting of liver ferroptosis.
机构信息
Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Suzhou Medical College of Soochow University, Soochow University, Suzhou, Jiangsu, China.
Liver Center, Massachusetts General Hospital, Boston, MA, USA.
出版信息
Cell Metab. 2024 Oct 1;36(10):2167-2169. doi: 10.1016/j.cmet.2024.09.005.
Metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with iron metabolism disorders and ferroptosis, but the mechanisms underlying this association remain unclear. Fudi Wang's group used animal models, human cohorts, and multi-omics data to demonstrate the role of iron imbalance in MAFLD and the therapeutic potential of the iron chelator FerroTerminator 1 (FOT1).
代谢相关脂肪性肝病（MAFLD）与铁代谢紊乱和铁死亡有关，但这种关联的机制尚不清楚。王府迪研究团队使用动物模型、人类队列和多组学数据，证明了铁失衡在 MAFLD 中的作用，以及铁螯合剂 FerroTerminator 1（FOT1）的治疗潜力。
Zotero 插件